Allena Pharmaceuticals, Inc.
(NASDAQ : ALNA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -1.45%141.180.7%$2226.77m
PFEPfizer Inc. 2.25%35.380.9%$1423.63m
MRKMerck & Co., Inc. 1.05%82.480.7%$1317.79m
ABBVAbbVie, Inc. 1.48%79.732.3%$1252.38m
BMYBristol-Myers Squibb Co. 1.06%58.871.0%$1127.60m
LLYEli Lilly & Co. -0.33%145.741.1%$866.97m
AZNAstraZeneca Plc 1.82%44.651.2%$292.10m
NVSNovartis AG -0.89%84.860.2%$267.33m
GSKGlaxoSmithKline Plc 2.10%38.880.2%$250.76m
NVONovo Nordisk A/S 0.89%60.170.1%$178.16m
SNYSanofi 0.62%45.460.2%$169.22m
FTSVForty Seven, Inc. 0.05%95.510.0%$138.72m
BHCBausch Health Cos., Inc. 14.92%18.020.0%$122.30m
RGENRepligen Corp. 2.54%98.957.1%$68.30m
RETAReata Pharmaceuticals, Inc. 2.74%141.193.4%$64.19m

Company Profile

Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults; and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Newton, MA.